QUB Prof Richard Wilson will present MErCuRIC at the EORTC-NCI-AARC Symposium

On November 16, 2018, MErCuRIC PI, Professor Richard Wilson of Queen’s University Belfast will present “A phase I dose escalation multi-centre study crizotinib (MET inhibitor) in patients with advanced solid tumours” during a “Molecular Targeted Agents” session of the EORTC-NCI-AACR Symposium. The meeting will take place on 13-16 November 2018 in The Convention Centre Dublin, in the Republic of Ireland.

Hosted by the European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR), the 2018 Symposium will assemble academics, scientists and pharmaceutical industry representatives from across the globe to discuss the latest innovations in drug development, target selection and the impact of new discoveries in molecular biology.

You can view the searchable EORTC- NCI- AACR Symposium 2018 programme here.


Queen’s University Belfast team makes a massive colon cancer breakthrough

New findings emerging from the research team at Queen’s University Belfast have identified a cellular process which can be exploited in order to kill BRAF mutant colon cancer cells, a particularly aggressive subgroup of colon cancers. These cancers are not only extremely aggressive but they do not respond well to conventional cancer treatments.

The QUB team behind the discovery describe it as a “ground-breaking therapeutic process that can target and kill bowel cancer cells”. The treatment will be a key tool in tackling the most aggressive form of the illness which conventional treatments have little or no impact on. The revolutionary technique may improve survival rates for colon cancer patients globally.

Professor Sandra Van Schaeybroeck, remarked: “This research is good news for bowel cancer patients as further clinical trials investigating the effect of such agents could improve the survival outcome of patients in Northern Ireland and beyond.”

Congratulations to all researchers involved!

Here is some digital press coverage of this story:







Belfast Telegraph

The Daily Mirror

The Newsletter

UNITO team publishes MErCuRIC study in Cancer Cell

A new MErCuRIC study from Prof Alberto Bardelli and the team at the University of Torino has just been published. The article entitled “Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer” was published on 9 July 2018 in Cancer Cell.

Congratulations to the entire research team: Giulia Siravegna, Luca Lazzari, Giovanni Crisafulli, Andrea Sartore-Bianchi, Benedetta Mussolin, Andrea Cassingena, Cosimo Martino, Richard B. Lanman, Rebecca J. Nagy, Stephen Fairclough, Giuseppe Rospo, Giorgio Corti, Alice Bartolini, Pamela Arcella, Monica Montone, Francesca Lodi, Annalisa Lorenzato, Alice Vanzati, Emanuele Valtorta, Giovanni Cappello, Andrea Bertotti, Sara Lonardi, Vittorina Zagonel, Francesco Leone, Mariangela Russo, Antonella Balsamo, Mauro Truini, Federica Di Nicolantonio, Alessio Amatu, Erica Bonazzina, Silvia Ghezzi, Daniele Regge, Angelo Vanzulli, Livio Trusolino, Salvatore Siena,  Silvia Marsoni and Alberto Bardelli.

The entire list of MErCuRIC publications can be found here: http://mercuric.eu/project/publications/

MErCuRIC celebrates International Clinical Trials Day 2018

In celebration of International Clinical Trials Day on 18 May 2018, an exhibition showcased cancer clinical studies in the Northern Ireland Cancer Centre. MErCuRIC and all open clinical studies where there was local leadership were promoted.

Patient representatives Margaret Grayson and Dr Edward Goodall were part of the team from the Northern Ireland Cancer Research Consumer Forum (NICRCF), Northern Ireland Cancer Trials Network  (NICTN) and several cancer charities who were on hand to share information and their own experience. There was a great support from staff, patients and visitors.


Esther Harding Shares Her Personal Experience of Participating in the MErCuRIC Study

Esther Harding (EH) spoke to Ruth Boyd* (RB) in the Northern Ireland Cancer Centre, May 2018. Esther is 69 years of age, lives in Northern Ireland and is married with 3 sons, 3 daughters-in-law and 7 grandchildren.

RB: Hello Esther, thank you for speaking to us about the MErCuRIC study. How long have you been taking part in the MErCuRIC trial?

EH: I am just in the second cycle of treatment in the study, so I do not know yet if the trial drugs have had any beneficial effect or not. I went on the study after I was told the cancer was in my liver and lungs and at the moment there is no suitable chemo for me. I was asked by one of the doctors involved with me if I would consider taking part in a clinical trial. The MErCuRIC study is for the stage of cancer I have and I was suitable as my primary cancer was in the bowel.

RB: What motivated you to take part in the trial?

EH: I have had the benefit of treatments and procedures and knew others had undergone trials towards these, also I know how important research is. I hope this trial proves to bring positive outcomes to those diagnosed with this type of bowel cancer in the future. My husband and I thought and prayed about it, faith is a big part of our lives, and although it was in my mind to say yes, I had to take into account what my family felt. They all thought, as my quality of life was good at the moment, it would be worthwhile to take part. They encouraged me in my decision and said to give the trial a go as I could pull out whenever I needed to, or if there are adverse effects it will be stopped.

It was reassuring the two drugs were already licensed and a placebo was not involved.

I was definitely motivated to take part if I was suitable. The process of finding out about suitability takes about 4 weeks, so I never felt under pressure.

RB: So when were you diagnosed and what treatment have you had already?

EH: I was diagnosed in December 2012 following colonoscopy after 7 months of various investigations for weight loss, headaches and then vomiting. I had bowel surgery in February 2013 and liver surgery 3 months later. Thankfully both consultants were excellent and very pleased with the outcome of my surgeries as my prognosis had been very dire. I then had 3 different types of chemo over the next 4 years and the last one before the trial was Lonsurf®. I was the first person in NI to receive this drug when it became available, and I got that for 9 months.

RB: What impact has cancer had?

EH: I had worked in administration and looked after grandchildren a few days a week. In general, I was very active. Up until I became ill I had been a hospice volunteer for many years which I loved. I enjoyed gardening and was involved in church life. Because I was very weak, all these activities came to a crashing halt.

Cancer changes individuals, but the impact on family life is huge. One of the most difficult parts is knowing all the folk who care about you are anxious and sad.

About early 2013 there was a Macmillan advert. It showed a few different scenarios of people being given news of cancer, and as they walk out of clinic etc. it looks like they are collapsing, legs giving way. Suddenly the hands of a Macmillan nurse appears to help– that’s the best representation I have seen of what it’s like to get the news its cancer and the importance of being offered help and advice.

RB: What’s it been like being on the MErCuRIC trial?

EH: I’d been ‘treatment free’ since before Christmas so I had tasted a bit of normality. Going on to the trial means you are back to hospital appointments, procedures and tests. A big reminder of cancer! It becomes quite an intense part of your life. At the start of the study there were biopsies and an overnight stay but now I know I generally now have a visit once a week. The upside of this is you are monitored so much – so if anything changes you know it’s going to be picked up, and if I don’t feel well I know I can say that. I have a PICC1 line for blood samples. I feel tired but it’s a general tiredness, it’s not like the fatigue I’ve had from chemotherapy before. A rash has been the most surprising side-effect of the treatment for me. The tests and biopsies have been grand.

Everything about the study was explained, nothing is hidden. It’s very open. My husband has been with me a lot. We have joked that at the end of this we should go and do a degree!

The doctors explained everything and the nurses have been brilliant. The staff are so good. When you are very ill you realise how important staff are and what a difference it makes when they are compassionate.

RB: Thank you so much for sharing your experience of taking part in this study.

1 PICC – Peripherally Inserted Central Catheter (inserted into a vein)

*Ruth Boyd is Cancer Research UK Senior Nurse in the NI Cancer Trials Network (NICTN) based at the NI Cancer Centre, Belfast HSC Trust, and is Personal and Public Involvement Professional Lead for the NI Cancer Research Consumer Forum (NICRCF). Belfast HSC Trust is a partner organisation of the MErCuRIC project funded by the European Community’s FP7 programme (contract #602901).

MErCuRIC explainer video is launched

The MErCuRIC three-minute explainer video was launched on 21 May 2018.

Please watch, utilize and share it!


MErCuRIC presented at the 2018 All-Ireland Colorectal Cancer Conference, Dublin

MErCuRIC will feature in a presentation facilitated by Dr Austin Duffy of the Mater Misericordiae Hospital, Dublin at the 2018 All Ireland Colorectal Cancer Conference. Dr Duffy’s talk is “Clinical Trials in Colorectal Cancer” will take place on Saturday, May 19th at the Gibson Hotel, Dublin, Ireland.

This 2-day conference assembles healthcare professionals with a faculty of national and international gastroenterology, medical oncology, pathology, radiation, surgical and scientific experts from Europe and North America. The meeting will provide participants with the opportunity to facilitate best practice by discussing and disseminating the latest trends and developments in treatment and therapy of colorectal cancers, whilst also affording the opportunity to network with medical and surgical peers.

See the complete programme here.

Margaret Grayson receives Iris Colvin Lifetime Achievement Award for Health

On April 21, 2018, valued MErCuRIC PPI team member Margaret Grayson received the Iris Colvin Lifetime Achievement Award for Health, presented by the Women’s Forum NI (Northern Ireland, UK) at Belfast City Hall. The award is bestowed in recognition of the lifetime achievement of a woman in service, dedication and commitment, and in this instance to health.

The aims of the award are to recognise the contribution of women to society, promote the role of women and strengthen links between organisations, acknowledge how a woman has been a role model and inspired others around her, mark outstanding achievement at a personal level through service to others, acknowledge passion, drive and energy in what a woman has done in her lifetime, highlight inspirational leadership, provide encouragement to other women, and show the commitment and dedication of a woman to aspects of life and citizenship outside her own family.

Ruth Boyd, Cancer Research UK Senior Nurse/NICTN Deputy Director of the Northern Ireland Cancer Trials Network comments, “Margaret is an extremely worthy recipient of this award, as we are all aware!”

The entire MErCuRIC partnership congratulate Margaret!




‘Trialling tailored treatments for colorectal cancer’: A European Commission Research & Innovation Success Story

MErCuRIC was featured as a Horizon 2020 Success Story on the European Commission’s Policies, information and services webpage on April 14, 2018. Below is an excerpt from the story.

“Made-to-measure treatments are becoming possible because of the growing understanding of the genetic and molecular nature of cancers and disease in general,” says Coordinator Sandra Van Schaeybroeck of Queen’s University Belfast. As well as offering welcome benefits to future colorectal cancer sufferers, MErCuRIC is an example of where medical treatment is heading.

“MERCURIC focuses on a particular sub-group of CRC patients. However, this ‘stratified’ approach beginning with a genetic and molecular profile of a patient can, and is, increasingly applied to many cancers and other disease groups.”

Read the entire story here.

MErCuRIC Europa-Research&Innovation

MErCuRIC study published in Molecular Cancer Therapeutics

The MErCuRIC study ‘The unfolded protein response: a novel therapeutic target for poor prognostic BRAF mutant colorectal cancer’ has been recently published in Molecular Cancer Therapeutics. The body of research by Nicholas Forsythe, Alaa Refaat, Arman Javadi, Hajrah Khawaja, Jessica-Anne Weir, Heba Emam, Wendy L Allen, Frank Burkamp, Vlad Popovici, Puthen V Jithesh, Claudio Isella, Melissa J LaBonte, Ian G Mills, Patrick G Johnston, and Sandra Van Schaeybroeck was accepted for publication on 16 February 2018.


BRAFV600E mutations occur in 10% of colorectal cancer (CRC) cases, are associated with poor survival and have limited responses to BRAF/MEK inhibition with or without EGFR inhibition. There is an unmet need to understand the biology of poor prognostic BRAFMT CRC. We have used differential gene expression and pathway analyses of untreated stage II and stage III BRAFMT (discovery set: n=31; validation set: n=26) CRC and an siRNA screen to characterize the biology underpinning the BRAFMT subgroup with poorest outcome. These analyses identified the unfolded protein response (UPR) as a novel and druggable pathway associated with the BRAFMT CRC subgroup with poorest outcome. We also found that oncogenic BRAF drives endoplasmic reticulum (ER) stress and unfolded protein response (UPR) pathway activation through MEK/ERK. Furthermore, inhibition of GRP78, the master regulator of the UPR, using siRNA or small molecule inhibition, resulted in acute ER stress and apoptosis, in particular in BRAFMT CRC cells. In addition, dual targeting of protein degradation using combined Carfilzomib (proteasome inhibitor) and ACY-1215 (HDAC6-selective inhibitor) treatment resulted in marked accumulation of protein aggregates, acute ER stress, apoptosis and therapeutic efficacy in BRAFMT in vitro and xenograft models. Mechanistically, we found that the apoptosis following combined Carfilzomib/ACY-1215 treatment is mediated through increased CHOP expression. Taken together, our findings indicate that oncogenic BRAF induces chronic ER stress and that inducers of acute ER stress could be a novel treatment strategy for poor prognostic BRAFMT CRC.


Read about the roles of the partner organizations within MErCuRIC here.

doi: 10.1158/1535-7163.MCT-17-0603. [Epub ahead of print]

Read the complete publication here.

Published 18 February 2018